Moon Surgical

Executive Summary

Moon Surgical is a Paris-based medical device company founded in 2019, dedicated to advancing minimally invasive surgery through its Maestro System, a robotic platform designed to enhance laparoscopic procedures. The system aims to improve surgeon ergonomics, procedural efficiency, and patient outcomes while reducing the cost and complexity of robotic surgery. By focusing on a sustainable and digitalized operating room, Moon Surgical addresses key pain points in current surgical robotics, such as high capital expenditure and limited accessibility. The company's technology has the potential to democratize robotic assistance in general surgery and other subspecialties. Despite promising preclinical and early clinical data, Moon Surgical remains in a growth phase without disclosed revenue or regulatory approvals. The company faces competition from established players like Intuitive Surgical and emerging startups. Key near-term milestones include European regulatory clearance and initial commercial launches. If successful, Moon Surgical could capture a meaningful share of the surgical robotics market. However, execution risks, funding requirements, and regulatory hurdles are significant. The company's value proposition hinges on demonstrating clinical superiority and cost-effectiveness in large-scale trials.

Upcoming Catalysts (preview)

• Q4 2026CE Mark Approval for Maestro System60% success
• H1 2027Pivotal Clinical Trial Results50% success
• Q3 2026Strategic Partnership or Series C Funding70% success